Merck has launched two new advanced fertility technologies; Eeva Test 3.0 and Geri for enhanced efficiency in the assisted reproductive treatment (ART) lab.
The combination platform will provide in-depth information and control over the environment in which the embryo grows to ensure healthy development and assessment.
With the established Xtend Algorithm, the Eeva Test 3.0 software supports embryo assessment in the ART lab.
Created by Australia-based fertility technologies firm Genea Biomedx, Geri can be used to optimise culture conditions based on the needs.
The newly launched Geri features a specially designed humidifier that enables precise monitoring and managing of the humidity level in the incubator.
Merck biopharma business chief marketing and strategy officer Rehan Verjee said: "We believe Merck fertility technologies can accelerate clinics toward a new standard for ART success
"Since 2014 we've launched 28 products in five product groups, providing new, state-of-the-art solutions that advance fertility care."
Geri features a real-time camera to monitor progress of embryo development, as well as provides humidified incubation in individual chambers to decrease disruptive events to the early-stage embryo.
It also includes Geri Connect software to monitor embryos in real time via remote access to patient and embryo data connected on the same network, and the user-defined scoring Geri Assess software to assess and grade embryos on their viability.
Integrating bright and dark-field imaging, the Eeva Test 3.0 and the Geri incubator combination facilitates the application of Eeva's assessment algorithm to support outcome prediction with individualised incubation.